STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway

KRAS is frequently mutated in patients with lung cancers, resulting in low survival rates. Inhibiting the downstream pathways of KRAS seems to be a feasible strategy to target KRAS-mutant tumors. However, the clinical outcomes only show limited success. Here, we developed a novel strategy by combini...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhenlin, Yin, Mengchen, Chu, Peilin, Lou, Meiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756870/
https://www.ncbi.nlm.nih.gov/pubmed/31484165
http://dx.doi.org/10.18632/aging.102244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756870/
https://www.ncbi.nlm.nih.gov/pubmed/31484165
http://dx.doi.org/10.18632/aging.102244

Ejemplares similares